It can be concluded that within the range of CBZ immediate release tablets that have a qualitative composition
comparable to the products studied (Table 1), dissolution
testing according to the USP method and speci®cation is a
reliable predictor of bioequivalence. Thus, this method and
speci®cation can be used to evaluate bioequivalence
between brands and within one brand, and also changes in
manufacturing site, storage time, storage condition, and
composition of products, without performing in vivo